
Tecentriq 1200mg Wbhs New Injection
Marketer
Roche Products India Pvt Ltd
Salt Composition
Atezolizumab (1200mg)
Overview Tecentriq 1200mg Wbhs New Injection
Atezolizumab 1200mg, a novel intravenous formulation, classifies as a monoclonal antibody therapy. Indicated for treating non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma, it's administered intravenously under medical supervision. Dosage and frequency are determined by your physician based on your condition and may vary. Adhere strictly to prescribed instructions; incorrect usage or overdose can lead to severe adverse events. Therapeutic benefits might not be apparent immediately; continue treatment unless directed otherwise by your doctor. Common side effects include tiredness, nausea, reduced appetite, constipation, cough, and breathlessness. Seek immediate medical attention for chest pain, diarrhea, or dark urine. Report any concerning side effects; management strategies may be available. Prior to treatment, disclose any heart, liver, or kidney conditions, or the use of antimicrobial medications. Significant drug interactions are possible; inform your healthcare provider of all concurrent medications. This medication is contraindicated during pregnancy and lactation; reliable contraception is crucial for both partners throughout treatment.
Uses of Tecentriq 1200mg Wbhs New Injection
Therapeutic approaches for small cell lung carcinoma, non-small cell lung carcinoma, melanoma, and hepatocellular carcinoma.
Major Benefits of Tecentriq 1200mg Wbhs New Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Tecentriq 1200mg Wbhs New Injection:
- Fatigue
- Weakness
- Decreased appetite
- Nausea
- Cough
- Breathlessness
- Constipation
How to use Tecentriq 1200mg Wbhs New Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Tecentriq 1200mg Wbhs New Injection works:
Atezolizumab, administered as a 1200mg intravenous infusion, is a monoclonal antibody therapy. Its mechanism involves inhibiting a protein expressed on T lymphocytes, a subset of white blood cells crucial for immune regulation. This blockade reactivates T-cell cytotoxicity, thereby enhancing the immune system's ability to identify and eliminate malignant cells.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Tecentriq 1200mg Wbhs New Injection is not considered safe, and medical advice is recommended.
PregnancyCONSULT YOUR DOCTOR
The use of Tecentriq 1200mg Wbhs New Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Patient consultation with their doctor is advised.
Breast feedingCONSULT YOUR DOCTOR
Atezolizumab 1200mg intravenous formulation is likely not safe for use while breastfeeding. Available human data indicates potential transfer to breast milk with a risk of infant harm.
DrivingCONSULT YOUR DOCTOR
The impact of Tecentriq 1200mg Wbhs New Injection on driving ability is undetermined. Refrain from operating a vehicle if you experience symptoms impairing concentration or reaction time.
KidneyCONSULT YOUR DOCTOR
Data regarding the administration of 1200mg Tecentriq subcutaneous injection to individuals with renal impairment is scarce. Physician consultation is recommended.
LiverCONSULT YOUR DOCTOR
Data regarding the administration of 1200mg Tecentriq intravenous solution to individuals with hepatic impairment is currently scarce. Physician consultation is advised.
What if you forget to take Tecentriq 1200mg Wbhs New Injection :
NA
Facts to Know About Tecentriq 1200mg Wbhs New Injection
| Label | Value |
|---|---|
| Chemical Type | Short protein chains |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Actions | PD-1 Checkpoint Blockade Therapy |
